Journal of the Korean Academy of Child and Adolescent Psychiatry

Korean Academy of Child and Adolescent Psychiatry (대한소아청소년정신의학회)
권호 표지
DOI QR코드

DOI QR Code

Stimulant Induced Movement Disorders in Attention Deficit Hyperactivity Disorder

  • Nam, Seok-Hyun (Department of Psychiatry, Jeonbuk National University Hospital) ;
  • Lim, Myung Ho (Department of Psychology, College of Public Human Resources, Dankook University) ;
  • Park, Tae Won (Department of Psychiatry, Jeonbuk National University Hospital)
  • Received : 2021.12.22
  • Accepted : 2022.01.19
  • Published : 2022.04.01
Download PDF
⟨ Previous Next ⟩

Abstract

Stimulants, such as amphetamine and methylphenidate, are one of the most effective treatment modalities for attention deficit hyperactivity disorder (ADHD) and may cause various movement disorders. This review discusses various movement disorders related to stimulant use in the treatment of ADHD. We reviewed the current knowledge on various movement disorders that may be related to the therapeutic use of stimulants in patients with ADHD. Recent findings suggest that the use of stimulants and the onset/aggravation of tics are more likely to be coincidental. In rare cases, stimulants may cause stereotypies, chorea, and dyskinesia, in addition to tics. Some epidemiological studies have suggested that stimulants used for the treatment of ADHD may cause Parkinson's disease (PD) after adulthood. However, there is still a lack of evidence that the use of stimulants in patients with ADHD may cause PD, and related studies are only in the early stages. As stimulants are one of the most commonly used medications in children and adolescents, close observations and studies are necessary to assess the effects of stimulants on various movement disorders, including tic disorders and Parkinson's disease.

Keywords

References

  1. Brown RT, Freeman WS, Perrin JM, Stein MT, Amler RW, Feldman HM, et al. Prevalence and assessment of attention-deficit/hyperactivity disorder in primary care settings. Pediatrics 2001;107: E43.
  2. Biederman J, Petty CR, Evans M, Small J, Faraone SV. How persistent is ADHD? A controlled 10-year follow-up study of boys with ADHD. Psychiatry Res 2010;177:299-304. https://doi.org/10.1016/j.psychres.2009.12.010
  3. Weiss G, Hechtman L, Milroy T, Perlman T. Psychiatric status of hyperactives as adults: a controlled prospective 15-year follow-up of 63 hyperactive children. J Am Acad Child Psychiatry 1985;24: 211-220. https://doi.org/10.1016/S0002-7138(09)60450-7
  4. Larson K, Russ SA, Kahn RS, Halfon N. Patterns of comorbidity, functioning, and service use for US children with ADHD, 2007. Pediatrics 2011;127:462-470. https://doi.org/10.1542/peds.2010-0165
  5. The MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:1073-1086. https://doi.org/10.1001/archpsyc.56.12.1073
  6. Cortese S, Adamo N, Del Giovane C, Mohr-Jensen C, Hayes AJ, Carucci S, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry 2018;5:727-738. https://doi.org/10.1016/S2215-0366(18)30269-4
  7. Faraone SV. Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. P T 2009;34:678-694.
  8. Baumeister AA, Henderson K, Pow JL, Advokat C. The early history of the neuroscience of attention-deficit/hyperactivity disorder. J Hist Neurosci 2012;21:263-279. https://doi.org/10.1080/0964704X.2011.595649
  9. Zito JM, Safer DJ, DosReis S, Gardner JF, Magder L, Soeken K, et al. Psychotropic practice patterns for youth: a 10-year perspective. Arch Pediatr Adolesc Med 2003;157:17-25. https://doi.org/10.1001/archpedi.157.1.17
  10. Scheffler RM, Hinshaw SP, Modrek S, Levine P. The global market for ADHD medications. Health Aff (Millwood) 2007;26:450-457. https://doi.org/10.1377/hlthaff.26.2.450
  11. Piper BJ, Ogden CL, Simoyan OM, Chung DY, Caggiano JF, Nichols SD, et al. Trends in use of prescription stimulants in the United States and territories, 2006 to 2016. PLoS One 2018;13:e0206100.
  12. Asser A, Taba P. Psychostimulants and movement disorders. Front Neurol 2015;6:75.
  13. Leckman JF, Zhang H, Vitale A, Lahnin F, Lynch K, Bondi C, et al. Course of tic severity in Tourette syndrome: the first two decades. Pediatrics 1998;102:14-19. https://doi.org/10.1542/peds.102.1.14
  14. Knight T, Steeves T, Day L, Lowerison M, Jette N, Pringsheim T. Prevalence of tic disorders: a systematic review and meta-analysis. Pediatr Neurol 2012;47:77-90. https://doi.org/10.1016/j.pediatrneurol.2012.05.002
  15. Freeman RD, Fast DK, Burd L, Kerbeshian J, Robertson MM, Sandor P. An international perspective on Tourette syndrome: selected findings from 3,500 individuals in 22 countries. Dev Med Child Neurol 2000;42:436-447. https://doi.org/10.1017/S0012162200000839
  16. Swanson J, Lerner M, March J, Gresham FM. Assessment and intervention for attention-deficit/hyperactivity disorder in the schools. Lessons from the MTA study. Pediatr Clin North Am 1999;46:993-1009 https://doi.org/10.1016/S0031-3955(05)70168-1
  17. Steinhausen HC, Novik TS, Baldursson G, Curatolo P, Lorenzo MJ, Rodrigues Pereira R, et al. Co-existing psychiatric problems in ADHD in the ADORE cohort. Eur Child Adolesc Psychiatry 2006; 15 Suppl 1:I25-I29. https://doi.org/10.1007/s00787-006-1004-y
  18. Leckman JF. Tourette's syndrome. Lancet 2002;360:1577-1586. https://doi.org/10.1016/S0140-6736(02)11526-1
  19. Golden GS. Gilles de la Tourette's syndrome following methylphenidate administration. Dev Med Child Neurol 1974;16:76-78. https://doi.org/10.1111/j.1469-8749.1974.tb02715.x
  20. Lowe TL, Cohen DJ, Detlor J, Kremenitzer MW, Shaywitz BA. Stimulant medications precipitate Tourette's syndrome. JAMA 1982;247:1168-1169. https://doi.org/10.1001/jama.1982.03320330064029
  21. Sverd J, Gadow KD, Paolicelli LM. Methylphenidate treatment of attention-deficit hyperactivity disorder in boys with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1989;28:574-579; discussion 580-582. https://doi.org/10.1097/00004583-198907000-00016
  22. Castellanos FX, Giedd JN, Elia J, Marsh WL, Ritchie GF, Hamburger SD, et al. Controlled stimulant treatment of ADHD and comorbid Tourette's syndrome: effects of stimulant and dose. J Am Acad Child Adolesc Psychiatry 1997;36:589-596. https://doi.org/10.1097/00004583-199705000-00008
  23. Gadow KD, Sverd J, Nolan EE, Sprafkin J, Schneider J. Immediate-release methylphenidate for ADHD in children with comorbid chronic multiple tic disorder. J Am Acad Child Adolesc Psychiatry 2007;46:840-848. https://doi.org/10.1097/chi.0b013e31805c0860
  24. Tourette's Syndrome Study Group. Treatment of ADHD in children with tics: a randomized controlled trial. Neurology 2002;58: 527-536. https://doi.org/10.1212/WNL.58.4.527
  25. Nolan EE, Gadow KD, Sprafkin J. Stimulant medication withdrawal during long-term therapy in children with comorbid attention-deficit hyperactivity disorder and chronic multiple tic disorder. Pediatrics 1999;103:730-737. https://doi.org/10.1542/peds.103.4.730
  26. Shapiro AK, Shapiro E. Do stimulants provoke, cause, or exacerbate tics and Tourette syndrome? Compr Psychiatry 1981;22:265-273. https://doi.org/10.1016/0010-440X(81)90084-5
  27. Erenberg G, Cruse RP, Rothner AD. Gilles de la Tourette's syndrome: effects of stimulant drugs. Neurology 1985;35:1346-1348. https://doi.org/10.1212/WNL.35.9.1346
  28. Rizzo R, Gulisano M, Cali PV, Curatolo P. Tourette syndrome and comorbid ADHD: current pharmacological treatment options. Eur J Paediatr Neurol 2013;17:421-428. https://doi.org/10.1016/j.ejpn.2013.01.005
  29. Scahill L, Specht M, Page C. The prevalence of tic disorders and clinical characteristics in children. J Obsessive Compuls Relat Disord 2014;3:394-400. https://doi.org/10.1016/j.jocrd.2014.06.002
  30. Varley CK, Vincent J, Varley P, Calderon R. Emergence of tics in children with attention deficit hyperactivity disorder treated with stimulant medications. Compr Psychiatry 2001;42:228-233. https://doi.org/10.1053/comp.2001.23145
  31. Spencer T, Biederman M, Coffey B, Geller D, Wilens T, Faraone S. The 4-year course of tic disorders in boys with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 1999;56:842-847. https://doi.org/10.1001/archpsyc.56.9.842
  32. Bloch MH, Leckman JF. Clinical course of Tourette syndrome. J Psychosom Res 2009;67:497-501. https://doi.org/10.1016/j.jpsychores.2009.09.002
  33. Harris EL, Schuerholz LJ, Singer HS, Reader MJ, Brown JE, Cox C, et al. Executive function in children with Tourette syndrome and/ or attention deficit hyperactivity disorder. J Int Neuropsychol Soc 1995;1:511-516. https://doi.org/10.1017/S1355617700000631
  34. Schuerholz LJ, Baumgardner TL, Singer HS, Reiss AL, Denckla MB. Neuropsychological status of children with Tourette's syndrome with and without attention deficit hyperactivity disorder. Neurology 1996;46:958-965. https://doi.org/10.1212/WNL.46.4.958
  35. Sherman EM, Shepard L, Joschko M, Freeman RD. Sustained attention and impulsivity in children with Tourette syndrome: comorbidity and confounds. J Clin Exp Neuropsychol 1998;20:644-657. https://doi.org/10.1076/jcen.20.5.644.1118
  36. Stokes A, Bawden HN, Camfield PR, Backman JE, Dooley JM. Peer problems in Tourette's disorder. Pediatrics 1991;87:936-942. https://doi.org/10.1542/peds.87.6.936
  37. Pierre CB, Nolan EE, Gadow KD, Sverd J, Sprafkin J. Comparison of internalizing and externalizing symptoms in children with attention-deficit hyperactivity disorder with and without comorbid tic disorder. J Dev Behav Pediatr 1999;20:170-176. https://doi.org/10.1097/00004703-199906000-00006
  38. Budman CL, Bruun RD, Park KS, Olson ME. Rage attacks in children and adolescents with Tourette's disorder: a pilot study. J Clin Psychiatry 1998;59:576-580. https://doi.org/10.4088/JCP.v59n1103
  39. Sukhodolsky DG, Scahill L, Zhang H, Peterson BS, King RA, Lombroso PJ, et al. Disruptive behavior in children with Tourette's syndrome: association with ADHD comorbidity, tic severity, and functional impairment. J Am Acad Child Adolesc Psychiatry 2003; 42:98-105. https://doi.org/10.1097/00004583-200301000-00016
  40. Bloch MH, Panza KE, Landeros-Weisenberger A, Leckman JF. Meta-analysis: treatment of attention-deficit/hyperactivity disorder in children with comorbid tic disorders. J Am Acad Child Adolesc Psychiatry 2009;48:884-893. https://doi.org/10.1097/CHI.0b013e3181b26e9f
  41. Cohen SC, Mulqueen JM, Ferracioli-Oda E, Stuckelman ZD, Coughlin CG, Leckman JF, et al. Meta-analysis: risk of tics associated with psychostimulant use in randomized, placebo-controlled trials. J Am Acad Child Adolesc Psychiatry 2015;54:728-736. https://doi.org/10.1016/j.jaac.2015.06.011
  42. Wilens TE, Spencer TJ, Swanson JM, Connor DF, Cantwell D. Combining methylphenidate and clonidine: a clinically sound medication option. J Am Acad Child Adolesc Psychiatry 1999;38:614-619; discussion 619-622. https://doi.org/10.1097/00004583-199905000-00025
  43. Lopez W, Jeste DV. Movement disorders and substance abuse. Psychiatr Serv 1997;48:634-636. https://doi.org/10.1176/ps.48.5.634
  44. Randrup A, Munkvad I. Stereotyped activities produced by amphetamine in several animal species and man. Psychopharmacologia 1967;11:300-310. https://doi.org/10.1007/BF00404607
  45. Rylander G. Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs. Psychiatr Neurol Neurochir 1972;75:203-212.
  46. Mattson RH, Calverley JR. Dextroamphetamine-sulfate-induced dyskinesias. JAMA 1968;204:400-402. https://doi.org/10.1001/jama.1968.03140180050018
  47. Melvin KE, Heiraty P. Acute chorea in a child after starting methylphenidate: a case report. Cureus 2013;5:e90.
  48. Ekinci O, Yasoz C, Ipek Bas SA, Ekinci N, Ipek Dogan O. Methylphenidate-induced exacerbation of chorea in a child resolved with switching to atomoxetine. Clin Psychopharmacol Neurosci 2020; 18:327-330. https://doi.org/10.9758/cpn.2020.18.2.327
  49. Gilbert DL. Acute and chronic chorea in childhood. Semin Pediatr Neurol 2009;16:71-76. https://doi.org/10.1016/j.spen.2009.03.009
  50. Balazs J, Dallos G, Kereszteny A, Czobor P, Gadoros J. Methylphenidate treatment and dyskinesia in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2011;21: 133-138. https://doi.org/10.1089/cap.2010.0030
  51. Kereszteny A, Ferenczi-Dallos G, Velo S, Gadoros J, Balazs J. Dyskinesia in treatment-naive and stimulant-treated children with ADHD. J Atten Disord 2020;24:981-989. https://doi.org/10.1177/1087054716679262
  52. Van Den Eeden SK, Tanner CM, Bernstein AL, Fross RD, Leimpeter A, Bloch DA, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol 2003;157: 1015-1022. https://doi.org/10.1093/aje/kwg068
  53. Goldman JG, Postuma R. Premotor and nonmotor features of Parkinson's disease. Curr Opin Neurol 2014;27:434-441. https://doi.org/10.1097/WCO.0000000000000112
  54. Subramaniam M, Althof D, Gispert S, Schwenk J, Auburger G, Kulik A, et al. Mutant α-synuclein enhances firing frequencies in dopamine substantia nigra neurons by oxidative impairment of Atype potassium channels. J Neurosci 2014;34:13568-13599.
  55. Beyer K, Domingo-Sabat M, Ariza A. Molecular pathology of Lewy body diseases. Int J Mol Sci 2009;10:724-745. https://doi.org/10.3390/ijms10030724
  56. Baumeister AA. Is attention-deficit/hyperactivity disorder a risk syndrome for Parkinson's disease? Harv Rev Psychiatry 2021;29: 142-158. https://doi.org/10.1097/HRP.0000000000000283
  57. Berg D, Behnke S, Seppi K, Godau J, Lerche S, Mahlknecht P, et al. Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease. Mov Disord 2013;28:216-219. https://doi.org/10.1002/mds.25192
  58. Krauel K, Feldhaus HC, Simon A, Rehe C, Glaser M, Flechtner HH, et al. Increased echogenicity of the substantia nigra in children and adolescents with attention-deficit/hyperactivity disorder. Biol Psychiatry 2010;68:352-358. https://doi.org/10.1016/j.biopsych.2010.01.013
  59. Fusar-Poli P, Rubia K, Rossi G, Sartori G, Balottin U. Striatal dopamine transporter alterations in ADHD: pathophysiology or adaptation to psychostimulants? A meta-analysis. Am J Psychiatry 2012;169:264-272. https://doi.org/10.1176/appi.ajp.2011.11060940
  60. Caminiti SP, Presotto L, Baroncini D, Garibotto V, Moresco RM, Gianolli L, et al. Axonal damage and loss of connectivity in nigrostriatal and mesolimbic dopamine pathways in early Parkinson's disease. Neuroimage Clin 2017;14:734-740. https://doi.org/10.1016/j.nicl.2017.03.011
  61. Halpin LE, Collins SA, Yamamoto BK. Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. Life Sci 2014;97:37-44. https://doi.org/10.1016/j.lfs.2013.07.014
  62. Wilson JM, Kalasinsky KS, Levey AI, Bergeron C, Reiber G, Anthony RM, et al. Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 1996;2:699-703. https://doi.org/10.1038/nm0696-699
  63. Moszczynska A, Fitzmaurice P, Ang L, Kalasinsky KS, Schmunk GA, Peretti FJ, et al. Why is parkinsonism not a feature of human methamphetamine users? Brain 2004;127:363-370. https://doi.org/10.1093/brain/awh046
  64. Baumeister AA. Could clinical use of stimulant medications increase risk for Parkinson's disease or other neurological sequelae? A review of the evidence. J Pharmacol Clin Res 2017;3:555618.
  65. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 2001;158:377-382. https://doi.org/10.1176/appi.ajp.158.3.377
  66. McCann UD, Kuwabara H, Kumar A, Palermo M, Abbey R, Brasic J, et al. Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 2008;62:91-100. https://doi.org/10.1002/syn.20471
  67. Rumpf JJ, Albers J, Fricke C, Mueller W, Classen J. Structural abnormality of substantia nigra induced by methamphetamine abuse. Mov Disord 2017;32:1784-1788. https://doi.org/10.1002/mds.27205
  68. Todd G, Pearson-Dennett V, Wilcox RA, Chau MT, Thoirs K, Thewlis D, et al. Adults with a history of illicit amphetamine use exhibit abnormal substantia nigra morphology and parkinsonism. Parkinsonism Relat Disord 2016;25:27-32. https://doi.org/10.1016/j.parkreldis.2016.02.019
  69. Todd G, Noyes C, Flavel SC, Della Vedova CB, Spyropoulos P, Chatterton B, et al. Illicit stimulant use is associated with abnormal substantia nigra morphology in humans. PLoS One 2013;8: e56438.
  70. Garwood ER, Bekele W, McCulloch CE, Christine CW. Amphetamine exposure is elevated in Parkinson's disease. Neurotoxicology 2006;27:1003-1006. https://doi.org/10.1016/j.neuro.2006.03.015
  71. Christine CW, Garwood ER, Schrock LE, Austin DE, McCulloch CE. Parkinsonism in patients with a history of amphetamine exposure. Mov Disord 2010;25:228-231. https://doi.org/10.1002/mds.22915
  72. Ludolph AG, Schaz U, Storch A, Liebau S, Fegert JM, Boeckers TM. Methylphenidate exerts no neurotoxic, but neuroprotective effects in vitro. J Neural Transm (Vienna) 2006;113:1927-1934. https://doi.org/10.1007/s00702-006-0487-5
  73. Zaczek R, Battaglia G, Contrera JF, Culp S, De Souza EB. Methylphenidate and pemoline do not cause depletion of rat brain monoamine markers similar to that observed with methamphetamine. Toxicol Appl Pharmacol 1989;100:227-233. https://doi.org/10.1016/0041-008X(89)90309-8
  74. Sadasivan S, Pond BB, Pani AK, Qu C, Jiao Y, Smeyne RJ. Methylphenidate exposure induces dopamine neuron loss and activation of microglia in the basal ganglia of mice. PLoS One 2012;7:e33693.
  75. Moll GH, Hause S, Ruther E, Rothenberger A, Huether G. Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters. J Child Adolesc Psychopharmacol 2001;11:15-24. https://doi.org/10.1089/104454601750143366
  76. Tebartz van Elst L, Maier S, Kloppel S, Graf E, Killius C, Rump M, et al. The effect of methylphenidate intake on brain structure in adults with ADHD in a placebo-controlled randomized trial. J Psychiatry Neurosci 2016;41:422-430. https://doi.org/10.1503/jpn.150320
  77. Kakish J, Lee D, Lee JS. Drugs that bind to α-synuclein: neuroprotective or neurotoxic? ACS Chem Neurosci 2015;6:1930-1940. https://doi.org/10.1021/acschemneuro.5b00172
  78. Camicioli R, Lea E, Nutt JG, Sexton G, Oken BS. Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: a pilot study. Clin Neuropharmacol 2001;24:208-213. https://doi.org/10.1097/00002826-200107000-00003
  79. Pollak L, Dobronevsky Y, Prohorov T, Bahunker S, Rabey JM. Low dose methylphenidate improves freezing in advanced Parkinson's disease during off-state. J Neural Transm Suppl 2007;72:145-148. https://doi.org/10.1007/978-3-211-73574-9_17
  80. Devos D, Krystkowiak P, Clement F, Dujardin K, Cottencin O, Waucquier N, et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 2007;78:470-475.
  81. Devos D, Moreau C, Delval A, Dujardin K, Defebvre L, Bordet R. Methylphenidate: a treatment for Parkinson's disease? CNS Drugs 2013;27:1-14.
  82. Drijgers RL, Verhey FR, Tissingh G, van Domburg PH, Aalten P, Leentjens AF. The role of the dopaminergic system in mood, motivation and cognition in Parkinson's disease: a double blind randomized placebo-controlled experimental challenge with pramipexole and methylphenidate. J Neurol Sci 2012;320:121-126. https://doi.org/10.1016/j.jns.2012.07.015
  83. Evans AH, Lawrence AD, Lees AJ. Changes in psychomotor effects of L-dopa and methylphenidate after sustained dopaminergic therapy in Parkinson's disease. J Neurol Neurosurg Psychiatry 2009;80:267-272. https://doi.org/10.1136/jnnp.2006.108993
  84. Moreau C, Delval A, Defebvre L, Dujardin K, Duhamel A, Petyt G, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol 2012;11:589-596. https://doi.org/10.1016/S1474-4422(12)70106-0
  85. Auriel E, Hausdorff JM, Giladi N. Methylphenidate for the treatment of Parkinson disease and other neurological disorders. Clin Neuropharmacol 2012;32:75-81. https://doi.org/10.1097/WNF.0b013e318170576c
  86. Mendonca DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord 2007;22:2070-2076. https://doi.org/10.1002/mds.21656
  87. Curtin K, Fleckenstein AE, Keeshin BR, Yurgelun-Todd DA, Renshaw PF, Smith KR, et al. Increased risk of diseases of the basal ganglia and cerebellum in patients with a history of attention-deficit/hyperactivity disorder. Neuropsychopharmacology 2018;43: 2548-2555. https://doi.org/10.1038/s41386-018-0207-5
  88. Geissler JM, Romanos M, Gerlach M, Berg D, Schulte C. No genetic association between attention-deficit/hyperactivity disorder (ADHD) and Parkinson's disease in nine ADHD candidate SNPs. Atten Defic Hyperact Disord 2017;9:121-127. https://doi.org/10.1007/s12402-017-0219-8